Implications of efavirenz for neuropsychiatry: A review

International Journal of Neuroscience

Volumn 120, Issue 12, 2010, Pages 739-745

  Cavalcante, G I T ^a   Capistrano Jr , V L M ^a   Cavalcante, F S D ^b   Vasconcelos, S M M ^a   MacDo, D S ^a   Sousa, F C F ^a   Woods, D J ^c   Fonteles, M M F ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Harmony Medical Center   (Brazil)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adverse effects; Central nervous system; Efavirenz; Neurochemistry; Neuropsychiatry; Neurotransmitters

Indexed keywords

EFAVIRENZ; INDINAVIR; RITONAVIR;

ANXIETY; CD4 LYMPHOCYTE COUNT; CONCENTRATION LOSS; CONFUSION; DEPRESSION; DIZZINESS; DREAMING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; HALLUCINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LETHARGY; NEUROPSYCHIATRY; NONHUMAN; REVIEW; SIDE EFFECT; SUICIDE; VIRUS LOAD; VIRUS REPLICATION;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; BENZOXAZINES; BRAIN; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; HUMANS;

EID: 78149244525     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2010.520541     Document Type: Review

References (69)

1. Aarnoutse, R. E., Grintjes, K. J. T., Telgt, D. S. C., Stek, M., Hugen, P. W. H., Reiss, P., et al. (2002). The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clinical Pharmacology & Therapeutics, 71, 57-67.
2. Aksenov, M., Aksenov, M., Butterfiel, D. A., & Markesbery, W. R. (2000). Oxidative modification of creatine kinase BB in Alzheimer's disease brain. Journal of Neurochemistry, 74, 2520-2527.
3. Albert, K. A., Hemmings, H. C., Adamo, A. I., Potkin, S. G., Akbarian, S., Sandman, C. A., et al. (2002). Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Archives of Gerontology Psychiatry, 59, 705-712.
4. Almond, L. M., Hoggard, P. G., Edirisinghe, D. E., Khoo, S. H., & Back, D. J. (2005). Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 56, 738-744.
5. Antoniou, T., & Tseng, A. L. (2002). Interactions between recreational drugs and antiretroviral agents. Annals of Pharmacotherapy, 36, 1596-1613.
6. Araújo, A. A. S., & Alves, I. R. A. (2002). Terapêutica Anti-retroviral: Situação atual e perspectivas da quimioterapia de combate ao HIV/AIDS. Cadernos - Centro Universitário São Camilo, 8, 96-108.
7. Arendt, G., Nocker, D., Von Giesen, H. J., & Nolting, T. (2007). Neuropsychiatric side effects of efavirenz therapy. Expert Opinion on Drug Safety, 6, 147-154.
8. Bickel, M., Stephan, C., Rottmann, C., Carlebach, A., Haberl, A., Kurowski, M., et al. (2005). Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. Scandinavian Journal of Infectious Diseases, 37, 520-252.
9. Blanch, J., Corbella, B., Garcia, F., Parellada, E., & Gatell, J. M. (2001). Manic syndrome associated with efavirenz overdose. Clinical Infectious Diseases, 15, 270-271.
10. Blanch, J., Martínez, E., Rousaud, A., José-Luis, B., García-Viejo, M. A., Peri, J. M., et al. (2001). Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. Journal of Acquired Immune Deficiency Syndromes, 27, 336-343.
11. Clercq, E. (2001). Antiviral drugs: Current state of the art. Journal of Clinical Virology, 22, 73-89.
12. Date, H. L., & Fisher, M. (2009). HIV infection. In R. Walker and C. Whittlesea (eds.), Clinical Pharmacy and Therapeutics, 4th ed. London: Churchill Livingstone Elsevier, 568-598.
13. David, S., Shoemaker, M., & Haley, B. E. (1998). Abnormal properties of creatine kinase in Alzheimer's disease brain: Correlation of reduced enzyme activity and active site photolabeling with aberrant cytosol-membrane partitioning. Molecular Brain Research, 54, 276-287.
14. Daya, S., Nonaka, K. O., Buzzel, G. R., & Reiter, J. R. (1989). Heme precursor 5-aminolevulinic acid alters brain tryptophan and serotonin levels without changing pineal serotonin and melatonin concentrations. Journal of Neuroscience Research, 23, 304-309.
15. de la Garza, C. L. S., Paoletti-Duarte, S., García-Martín, C., & Gutiérrez-Casares, J. R. (2001). Efavirenz-induced psychosis. AIDS, 15, 1911-1912.
16. Dursun, S. M., Blackburn, J. R., & Kutcher, S. P. (2001). An exploratory approach to the serotonergic hypothesis of depression: Bridging the synaptic gap. Medical Hypotheses, 56, 235-243.
17. Efavirenz. (2009). Sustiva. Rhodes, Greece: Cerner Multum.
18. Fumaz, C. R., Munõz-Moreno, J. A., Moltó, J., Negredo, E., Ferrer, M. J. M. A., Sirera, J., et al. (2005). Long-term neuropsychiatric disorders on efavirenz-based approaches: Quality of life, psychologic issues, and adherence. Journal of Acquired Immune Deficiency Syndromes, 38, 560-565.
19. Graeff, F. G., Guimaraes, F. S., De Andrade, T. G. C. S., & Deakin, J. F. W. (1996). Role of 5-HT in stress, anxiety, and depression. Pharmacology, Biochemistry, and Behavior, 54, 129-141.
20. Gutiérrez, F., Navarro, A., Padilla, S., Antón, R., Masiá, M., Borrás, J., et al. (2005). Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clinical Infectious Diseases, 41, 1648-1653.
21. Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. M., Gulick, R. M., et al. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trial Group study. AIDS, 18, 2391-400.
22. Hariparsad, N., Nallani, S. C., Sane, R. S., Buckley, D. J., Buckley, A. R., & Desai, P. B. (2004). Induction of CYP3A4 by efavirenz in primary human hepatocytes: Comparison with rifampin and phenobarbital. Journal of Clinical Pharmacology, 44, 1273-1281.
23. Hawkins, T., Geist, C., Young, B., Giblin, A., Mercier, R. C., Thornton, K., et al. (2005). Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clinical Trials, 6, 187-196.
24. Hesse, L. M., von Moltke, L. L., Shader, R. I., & Greenblatt, D. J. (2001). Ritonavir, efavirenz, and nelfnavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion. Drug Metabolism and Disposition, 29, 100-102.
25. Jena, A., Sachdeva, R. K., Sharma, A., & Wanchu, A. (2009). Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: A 24-week prospective study. Journal of the International Association of Physicians in AIDS Care, 8, 318-322.
26. Kato, T., & Kato, N. (2000). Mitochondrial dysfunction in bipolar disorder. Bipolar Disorders, 2, 180-190.
27. Konradi, C., Eaton, M., MacDonald, M. L., Walsh, J., Benes, F. M., & Heckers, S. (2004). Molecular evidence for mitochondrial dysfunction in bipolar disorder. Archives of Gerontology Psychiatry, 61, 300-308.
28. Langmann, P., Schirmer, D., Vath, T., Zilly, M., & Klinker, H. (2001). High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy. Journal of Chromatography. B, Biomedical Sciences and Applications, 755, 151-156.
29. Leonard, B. E., & Myint, A. (2006). Inflammation and depression: Is there a causal connection with dementia? Neurotoxicity Research, 10, 149-160.
30. Liu, P., Foster, G., LaBadie, R. R., Gutierrez, M. J., & Sharma, A. (2005). Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy subjects. Clinical Pharmacology & Therapeutics, 77, 40.
31. Lochet, P., Peyriere, H., Lotthé, A., Mauboussin, J. M., Delmas, B., & Reynes, J. (2003). Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Medicine, 4, 62-66.
32. Luin van, M., Brouwer, A. M., van der Ven, A., de Lange, W., van Schaik, R. H. N., & Burger, D. M. (2009). Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin. AIDS, 23, 742-744.
33. Maes, M., Meltzer, H. Y., Scharpe, S., Bosmans, E., Suy, E., De Meester, I., et al. (1993). Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Research, 49, 151-165.
34. Manji, H. K., Drevets, W. C., & Charney, D. S. (2001). The cellular neurobiology of depression. Nature Medicine, 7, 541-547.
35. Marwaha, A. (2008). Getting High on HIV Drugs in S Africa. Retrieved 10 August 2010, from http://news.bbc.co.uk/2/hi/africa/7768059.stm
36. Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., & Buclin, T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15, 71-75.
37. Ministério da Saúde (Brasil) & Programa Nacional DST/AIDS. (2004). Recomendações para terapia anti-retroviral em adultos e ado-lescentes infectados pelo HIV 2004. Brasília, Brazil: Ministério da Saúde.
38. Monshouwer, M., Witkamp, R. F., Nijmeijer, S. M., Van Amsterdam, J. G., & Van Miert, A. S. J. P. A. M. (1996). Supression of cytochrome P450 and UDP glucuronosyl transferase-dependent enzyme activies by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicology and Applied Pharmacology, 137, 237-244.
39. O'Mahony, S. M., Myint, A., Steinbusch, H., & Leonard, B. E. (2005). Efavirenz induces depressive like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation, 12, 293-298.
40. Park-Wyllie, L. Y., & Antoniou, T. (2003). Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: A case series. AIDS, 17, 638-640.
41. Paterson, D. L., Swindells, S., Brester, M., & Vergis, E. N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
42. Patroclo, M. A. A., & Medronho, R. A. (2007). Evolução da contagem de células T CD4+ de portadores de AIDS em contextos socialmente desiguais. Caderno de Saúde Pública, 23, 1955-1963.
43. P érez-Molina, J. A. (2002). Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1, 033 HIV-infected patients. HIV Clinical Trials, 3, 279-286.
44. Peyriere, H., Mauboussin, J. M., Rouanet, I., Fabre, J., & Reynes, J. (2001). Management of sudden psychiatric disorders related to efavirenz. AIDS, 15, 1323-1324.
45. Piacenti, F. J. (2006). An update and review of antiretroviral therapy. Pharmacotherapy, 26, 1111-1133.
46. Prabakaran, S., Swatton, J. E., Ryan, M. M., Huffaker, S. J., Huang, J. T. J., Griffin, J. L., et al. (2004). Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. Molecular Psychiatry, 9, 684-697.
47. Puzantian, T. (2002). Central nervous system adverse effects with efavirenz: Case report and review. Pharmacotherapy, 22, 930-933.
48. Quereda, C., Corral, I., Moreno, A., Péres-Elias, M. J., Casado, J. L., Dronda, F., et al. (2008). Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV coinfected patients. Journal of Acquired Immune Deficiency Syndromes, 49, 61-63.
49. Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005). Neuropsychiatric adverse effects of interferon-α: Recognition and management. CNS Drugs, 19, 105-123.
50. Rihs, T. A., Begley, K., Smith, D. E., Sarangapany, J., Callaghan, A., Kelly, M., et al. (2006). Efavirenz and chronic neuropsychiatric symptoms: A cross-sectional case control study. HIV Medicine, 7, 544-548.
51. Robbins, K. E., Lemey, P., Pybus, O. G., Jaffe, H. W., Youngpairoj, A. S., Brown, T. M., et al. (2003). Human immunodeficiency virus type 1 epidemic: Date of origin, population history, and characterization of early strains. Journal of Virology, 11, 59-66.
52. Romão, P. R. T., Lemos, J. C., Moreira, J., de Chaves, G., Moretti, M., Castro, A. A., et al. (2009). Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. Neurotoxicity Research. Accessed 10 August 2010, DOI: http://dx.doi.org/10.1007/si2640-009- 9141-y, ISSN1029-8428. [Epub ahead of print].
53. Rotger, M., Colombo, S., Furrer, H., Bleiber, G., Buclin, T., Lee, B. L., et al. (2005). Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV infected patients. Pharmacogenetics and Genomics, 15, 1-5.
54. Rothermundt, M., Missler, U., Arolt, V., Peters, M., Leadbeater, J., Wiesmann, M., et al. (2001). Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Molecular Psychiatry, 6, 445-449.
55. Sacktor, N., Lyles, R. H., Skolasky, R., Kleeberger, C., Selnes, O. A., Miller, E. N., et al. (2001). HIV-associated neurologic disease incidence changes: Multicenter AIDS cohort study, 1990-1998. Neurology, 56, 257-260.
56. Sanchez, H. V., & Gutierrez, R. F. (2008). Toxicogenetics of antiretroviral treatment (II): Neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs. Enfermedades Infecciosas y Microbiologia Clinica, 6, 24-33.
57. Sargent, P. A., Kjaer, K. H., Bench, C. J., Rabiner, E. A., Messa, C., Meyer, J., et al. (2000). Brain serotonin1A receptor binding measured by positron emission tomography with [11C] WAY-100635: Effects of depression and antidepressant treatment. Archives of General Psychiatry, 57, 174-180.
58. Skidmore-Roth, L. (2009). Mosby's Drug Guide of Nurses, 8th ed. St. Louis, MO: Mosby Elsevier, 346 pp.
59. Steffens, D. C., Plassman, B. L., Helms, M. J., Welsh-Bohmer, K. A., Saunders, A. M., & Breitner, J. C. (1997). A twin study of late-onset depression and apolipoprotein E4 as risk factors for Alzheimer's disease. Biological Psychiatry, 41, 851-856.
60. Streck, E. L., Amboni, G., Scaini, G., Di-Pietro, P. B., Rezin, G. T., Valvassori, S. S., et al. (2008). Brain creatine kinase activity in an animal model of mania. Life Sciences, 82, 424-429.
61. Streck, E. L., Scaini, G., Rezin, G. T., Moreira, J., Fochesato, C. M., & Romão, P. R. T. (2008). Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metabolic Brain Disease, 23, 485-492.
62. Tomimoto, H., Yamamoto, K., Homburger, H. A., & Yanagihara, T. (1993). Immunoelectron microscopic investigation of creatine kinase BB-isoenzyme after cerebral ischemia in gerbils. Acta Neuropathologica, 86, 447-455.
63. Treisman, G. J., & Kaplan, A. I. (2002). Neurologic and psychiatric complications of antiretroviral agents. AIDS, 16, 1201-1215.
64. *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochemical and Biophysical Research Communications, 319, 1322-1326.
65. Turner, B. G., & Summers, M. F. (1999). Structural biology of HIV. Journal of Molecular Biology, 285, 1-32.
66. von Giesen, H. J., Köller, H., Theisen, A., & Arendt, G. (2002). Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes, 29, 363-367.
67. Wallimann, T., Wys, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992). Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The "phosphocreatine circuit" for cellular energy homeostasis. Biochemical Journal, 281, 21-40.
68. Wande, A. N. (1994). Handbook of Pharmaceutical excipients, 2th ed. Washington, DC: American Pharmaceutical Association.
69. Zheve, G. T. (2007). Neuroprotective Mechanisms of Nevirapine and Efavirenz in Model of Neurodegeneration. Rhodes, Greece: Rhodes University.